Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target

Return only trials with results

Include all Phase 1 trials (i.e., dose-finding as well as expansion)

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

II

Recurrent ovarian cancer

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

II

Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rucaparib	Rubraca, CO-338, PF 01367338, AG-014699	PARP inhibitor	Approved in Ovarian Cancer

II

Granulosa cell ovarian cancer

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Methoxyamine	TRC102	Base excision repair inhibitor	Clinical Trials
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent	Approved in Other Cancers

II

Advanced solid tumors with lesion treatable with radiation therapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Irradiation, Radiotherapy

II

Recurrent clear cell ovarian cancer

BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

IL, RI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive high grade serous ovarian cancer (cohort A), or BRCA MUT or HRD+ platinum sensitive high grade serous ovarian cancer w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII)

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

MD, MA, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with CDK12 alterations

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

CA, MD, MI, MO, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer with dMMR, high MSI or high TMB

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

CA, NY, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ARID1A (except clear cell) or ATM alterations

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment

A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade

CT, NJ, NY, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Irradiation, Radiotherapy

II

Recurrent ovarian cancer

A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling

CA, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rintatolimod	Atvogen	TLR3 agonist and immune cell stimulator	Approved in Other Indications

II

Recurrent low grade serous ovarian cancer

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum

CA, FL, GA, IL, IN, MI, MN, NH, NJ, NM, OH, OK, PA, RI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Ribociclib	Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced solid tumors with prior PD-1/PD-L1 inhibitor therapy

An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy

CA, FL, IN, KY, LA, OK, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BI 754111		Blocks LAG-3 inhibition of T cells	Clinical Trials
BI 836880	anti-VEGF/ANG2 nanobody BI 836880	VEGF and Angiopoietin 2 antagonist	Clinical Trials
Ezabenlimab	anti-PD-1 monoclonal antibody BI 754091, BI 754091	Blocks PD-L1/2 inhibition of T cells	Clinical Trials

II

Recurrent ovarian cancer

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Stenoparib	PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121	PARP inhibitor	Clinical Trials

II

Recurrent PR+ low grade serous or granulosa cell ovarian cancer

Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor), Alone or In Combination With Anastrozole in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Anastrozole	Arimidex	Aromatase inhibitor
Onapristone ER	extended-release onapristone, ONA-XR	PR antagonist that blocks PR activation and the associated expression of PR-responsive genes

II

Advanced solid tumors with moderate/high TMB

Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

II

Advanced solid tumors (with tumor amenable to skin biopsy)

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with progression on prior immunotherapy or cellular therapy (amenable to radiation therapy)

Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Irradiation, Radiotherapy

II

Recurrent high grade ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin	Proleukin	IL-2 receptor agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
LN-145-S1	Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy	Immune response against tumor-associated antigens	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations

Genomically-Guided Treatment Trial in Brain Metastases

AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Paxalisib	GDC-0084, PI3K inhibitor GDC-0084, RG7666	PI3K/mTOR inhibitor	Clinical Trials

II

Advanced solid tumors with FGFR mutations or fusions

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

AZ, CO, FL, GA, ME, MA, NJ, NY, NC, OH, PA, TN, TX, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Erdafitinib	pan-FGFR tyrosine kinase inhibitor JNJ-42756493	pan-FGFR kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B/C/D

A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes

CA, FL, IL, IA, MA, NY, OH, OK, PA, TN, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Rucaparib	Rubraca, CO-338, PF 01367338, AG-014699	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with a NRG1 gene fusion

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

AL, AZ, CA, CO, DE, DC, FL, GA, HI, IL, MA, MI, MN, MO, NE, NY, NC, OH, OR, TN, TX, UT, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Seribantumab	SAR256212, MM-121	ERBB3 antagonist	Clinical Trials

II

Advanced solid tumors with dMMR, after prior immunotherapy

Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Sirolimus	Rapamycin, Rapamune	mTOR inhibitor	Approved in Other Indications

II

Recurrent rare tumors

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nilotinib	AMN 107, Tasigna	Bcr-abl, c-Kit, and PDGFR kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Recurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterations

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Anastrozole	Arimidex	Aromatase inhibitor
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer

II

Advanced HER2+ solid tumors

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

CA, IL, IN, MA, NJ, NY, NC, TN, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab deruxtecan	T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a	ADC: anti-HER2 + topoisomerase I inhibitor (Dxd)	Approved in Other Cancers

II

Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1

A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.

IN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Temuterkib	LY3214996	ERK inhibitor	Clinical Trials

II

Advanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; gBRCA MUT patients must have progressed on prior PARP inhibitor)

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

II

Advanced solid tumors with ATM mutations

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

CA, FL, IN, LA, MD, MI, NV, NY, PA, SC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials

II

Recurrent ovarian cancer

Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nemvaleukin alfa	ALKS4230, Nemvaleukin, intermediate-affinity interleukin-2 receptor agonist ALKS 4230	IL-2R beta and gamma agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2 AMP, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMB

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

AL, AZ, CA, DE, FL, GA, ID, IL, IN, ME, MD, MI, MN, MO, MT, NV, NJ, NM, NY, OH, OR, PA, SC, TN, TX, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Idasanutlin	RO5503781, RG7388, MDM2 antagonist RO5503781	MDM2 antagonist
Inavolisib	RG6114, GDC-0077	PI3K alpha inhibitor	Clinical Trials
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Recurrent low grade serous ovarian cancer

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

AZ, CA, CT, FL, IL, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials
VS-6766	CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766	RAF and MEK inhibitor	Clinical Trials

II

Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, PIK3CA, PTEN, RET, ROS1 or with high TMB or high MSI

MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

AL, AK, AZ, AR, CA, CT, FL, ID, LA, MD, MI, MO, MT, NE, NJ, NY, NC, OH, OR, TN, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Inavolisib	RG6114, GDC-0077	PI3K alpha inhibitor	Clinical Trials
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor	Approved in Other Cancers
Pralsetinib	BLU-667	RET-kinase inhibitor	Approved in Other Cancers
Tiragolumab	MTIG7192A, RO7092284	Blocks TIGIT binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells	Clinical Trials
Trastuzumab	Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody	HER2 antagonist	Approved in Other Cancers
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers
Tucatinib	Irbinitinib, ONT-380	HER2 kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with leptomeningeal metastases

Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors - intratumoral injection

A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer

AZ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Thermotherapy			Clinical Trials

II

Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avapritinib		PDGFRa and c-Kit inhibitor	Approved in Other Cancers

II

Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A

A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced solid tumors with FGFR1-4 alterations

A PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONS

AZ, CA, DC, IL, MD, MA, MI, OK, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Futibatinib	FGFR inhibitor TAS-120, TAS-120	FGFR1-4 inhibitor	Clinical Trials

II

Recurrent ovarian cancer with symptomatic ascites or pleural effusion

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
APL-2	C3-targeted complement inhibitor APL-2	Blocks the cleavage of C3	Approved in Other Indications
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ARID1A mutations

A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive FRalpha+ high grade serous ovarian cancer with ≥2 prior platinum regimens, not eligible for further platinum therapy; BRCA MUT patients must have had prior PARP inhibitor therapy

A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)

CO, NV, NJ, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Mirvetuximab soravtansine	M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate	ADC: anti-FOLR1 + microtubule destabilizer (DM4)	Clinical Trials

II

Advanced solid tumors with brain metastases

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive ovarian cancer with progression on prior PARP inhibitor (≤4 cytotoxic chemotherapy or DNA-damage response agents containing regimens)

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
ZEN-3694	ZEN003694, BET bromodomain inhibitor ZEN-3694	BET inhibitor	Clinical Trials

II

Recurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTEN

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Fulvestrant	Faslodex, ICI 182,780, ZD9238	ER antagonist (SERD)	Approved in Other Cancers

II

Advanced solid tumors with ALK or ROS1 fusions, BRAF V600X, gBRCA1/2, gPALB2 alterations, or HER2+ or Nectin-4+

Strata PATH (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Binimetinib	MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi	MEK inhibitor	Approved in Other Cancers
Encorafenib	Raf Kinase Inhibitor LGX818, LGX818	RAF inhibitor	Approved in Other Cancers
Enfortumab Vedotin		ADC: anti-Nectin-4 + microtubule destabilizer (MMAE)	Approved in Other Cancers
Lorlatinib	PF-06463922	ALK and ROS1 kinase inhibitor	Approved in Other Cancers
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
Trastuzumab deruxtecan	T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a	ADC: anti-HER2 + topoisomerase I inhibitor (Dxd)	Approved in Other Cancers

II

Recurrect low grade serous ovarian cancer

Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Fulvestrant	Faslodex, ICI 182,780, ZD9238	ER antagonist (SERD)	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers

II

Recurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV)

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nilotinib	AMN 107, Tasigna	Bcr-abl, c-Kit, and PDGFR kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

High grade ovarian cancer with primary platinum resistance or with stable disease after first-line therapy with no prior PARP inhibitor or high grade ovarian cancer with prior PARP inhibitor maintenance as most recent therapy

Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease & Are PARP Inhibitor naïve; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance

FL, GA, NY, PA, TN, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
EP0057	IT-101, cyclodextrin-based polymer-camptothecin CRLX101, camptothecin-polymer conjugate IT-101, CRLX101, NLG207	Topoisomerase I inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

II

Platinum resistant high grade serous or recurrent clear cell ovarian cancer (<2 prior chemotherapy regimens)

A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Vudalimab	XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717	Blocks PD-1 and CTLA-4 inhibition of T cells	Clinical Trials

Ib/IIa

Advanced solid tumors

An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors

FL, MI, MO, NC, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Efineptakin alfa	NT-I7, GX-I7, Hyleukin, recombinant human IL-7-hybrid Fc NT-I7, TJ107	IL-7R agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

Ib

Recurrent high grade serous ovarian cancer; BRCA MUT patients must have progression after PARP inhibitor maintenance therapy (in expansion)

A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

Ib

Advanced solid tumors that are TP53 WT with MDM2 AMP or MDM4 AMP (in expansion)

A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ALRN-6924	MDM2/MDMX inhibitor ALRN-6924	MDM2 and MDMX inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

Ib

Recurrent ovarian cancer

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

AZ, CA, LA, NJ, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer
TRK-950	monoclonal antibody TRK-950	Undisclosed mechanism	Clinical Trials

Ib

Advanced solid tumors with alterations in ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, PIK3CA (E542, E545 or H1047), POLD1, PPP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L or XRCC2 (in expansion)

A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors

CO, MA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

Ib

Advanced solid tumors or high grade serous platinum resistant or refractory ovarian cancer (ATRC-101+PLD)

A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies

AZ, CA, DC, FL, MA, MN, NY, NC, OK, TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ATRC-101		Anti-tumor immune response	Clinical Trials
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer

Ia/Ib

Advanced solid tumors (in ovarian expansion)

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

AZ, CA, CO, CT, DC, FL, GA, KY, MD, MA, MI, NJ, NY, OH, PA, TN, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ONC-392		Blocks CTLA-4 inhibition of T cells	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/IIa

Advanced solid tumors - intratumoral injection (Phase II)

A Phase I/IIA, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours

CA, OR

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AGI-134	αGal immunotherapy	Anti-tumor immune response

I/IIa

Advanced solid tumors (Phase II)

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

CA, CT, MA, NM, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
LNS8801	G protein-coupled estrogen receptor agonist LNS8801	GPER agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Recurrent ovarian cancer (Phase II)

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cediranib	Recentin, Cediranib maleate, AZD2171	VEGFR1-3 kinase inhibitor
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

I/II

Advanced solid tumors (Phase II)

A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

AR, MD, NJ, NY, OK, PA, TX, UT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
HuMax-IL8	MDX 018, anti-IL-8 monoclonal antibody HuMax-IL8, BMS-986253	IL-8 antagonist	Clinical Trials
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid tumors with RET alterations (Phase II)

A Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Selpercatinib	LOXO-292, RET kinase inhibitor LOXO-292, Retevmo	RET-kinase inhibitor	Approved in Other Cancers

I/II

Advanced solid tumor with high MSI or dMMR - intratumoral injection (Phase II)

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

AZ, CA, FL, IA, KY, NJ, NY, NC, OH, PA, SC, TN, UT, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
RP1	oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus	Induces immune response and tumor cell lysis	Clinical Trials

I/II

Advanced solid tumors (inc ovarian expansion)

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours

CA, MA, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
[225Ac]-FPI-1434		Radioimmunotherapy: anti-IGF-1R + Actinium-225	Clinical Trials

I/II

Advanced solid tumors (Phase II)

A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

NC, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
DSP-0509	toll-like receptor 7 agonist DSP-0509	TLR7 agonist and immune cell activator	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid tumors with alterations in ARID1A, CREBBP, EP300, or MYC or AR overexpression

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
CCS1477	p300 HAT/CREB binding protein inhibitor CCS1477, p300/CBP bromodomain inhibitor CCS1477, Inobrodib	p300/CBP inhibitor	Clinical Trials

I/II

Recurrent ovarian cancer with prior PARP inhibitor

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

AZ, CA, CO, FL, MA, MI, MN, NJ, NY, OK, PA, TN, TX, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
CYT-0851		RAD51 inhibitor
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer

I/II

Advanced solid tumors (Phase II)

Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BMS-986156		GITR (glucocorticoid-induced TNFR) agonist	Clinical Trials
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Irradiation, Radiotherapy

I/II

Platinum resistant or refractory high grade serous ovarian cancer (Phase II)

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer

CA, CO, IL, NY, OK, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
IMC-C103C	IMC-C103C, a T cell redirecting bi-specific biologic	Re-directs T cells to attack MAGE-A4+ tumor cells	Clinical Trials

I/II

Advanced solid tumors with PIK3CA mutations (E542, E545, or H1047) or PTEN mutations (Phase II)

A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors

MA, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II)

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, OH, PA, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Repotrectinib	ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005	ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor	Clinical Trials

I/II

Advanced solid tumors with oncogenic activation of the NF-κB pathway or amplification of c-IAP1 or c-IAP2 (Phase II)

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

AL, CA, CT, GA, IL, MD, MA, MI, NH, NJ, NY, NC, OH, OK, OR, PA, SC, TN, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Tolinapant	XIAP/cIAP1 antagonist ASTX660, ASTX660	IAP antagonist	Clinical Trials

I/II

Advanced solid tumors with MET AMP or MET gene fusions (Phase II)

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

AZ, CA, DE, FL, LA, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, UT, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bozitinib	APL-101, CBT-101, Vebreltinib	c-Met kinase inhibitor	Clinical Trials

I/II

Recurrent ovarian cancer

Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)

FL, IL, MA, MI, NY, OH, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cemiplimab	anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
REGN4018	anti-MUC16/CD3 bispecific antibody REGN4018	Re-directs T cells to attack MUC16 (CA125)+ tumor cells	Clinical Trials
REGN5668		Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cells	Clinical Trials

I/II

Advanced solid tumors with a RET alteration (Phase II)

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

AZ, CA, CO, DC, FL, MD, MA, MI, MN, MO, NY, OR, PA, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pralsetinib	BLU-667	RET-kinase inhibitor	Approved in Other Cancers

I/II

Recurrent high grade serous or endometrioid ovarian cancer or advanced solid tumors with high TMB that are MS-Stable

A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)

AZ, CA, FL, MA, MI, MN, NY, NC, OK, TN, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Etigilimab	anti-TIGIT OMP-313M32, OMP-313M32	Blocks TIGIT binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Platinum sensitive ovarian cancer

An Open-label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin in Combination With Other Agent(s) In Participants With High-grade Serous Ovarian Cancer (UPGRADE)

MA, MI, PA, SC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Upifitamab rilsodotin	XMT-1536, UpRi	ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA)	Clinical Trials

I/II

Advanced solid tumors with cutaneous or subcutaneous lesions - intratumoral injection (Phase II)

A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 When Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

AZ, MA, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
T3011	oncolytic HSV-1-expressing IL-12 and anti-PD-1 antibody T3011	Induces immune response and tumor cell lysis	Clinical Trials

I

Advanced solid tumors including those with BRCA1/2 mutations (in expansion)

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dinaciclib	CDK inhibitor SCH 727965, SCH 727965	CDK1, 2, 5, 9 inhibitor	Clinical Trials
Veliparib	ABT-888	PARP inhibitor	Clinical Trials

I

Platinum sensitive ovarian cancer that is BRCA MUT or with RAD51C/D mut or HRD+ with prior progression on a PARP inhibitor, no prior ATR inhibitor

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.

CA, MA, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

I

Advanced solid tumors (in ovarian expansion)

Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abexinostat	PCI-24781, HDAC inhibitor CRA-024781	HDAC inhibitor	Clinical Trials
Pazopanib	Votrient	Multi-targeted RTK inhibitor

I

Advanced solid tumors (in expansion)

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors

CA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Favezelimab	anti-LAG3 monoclonal antibody MK-4280, MK-4280	Blocks LAG-3 inhibition of T cells	Clinical Trials
Irinotecan	Campothecin-11, Campto, Camptosar	Topoisomerase I inhibitor	NCCN Guidelines for Ovarian Cancer
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Oxaliplatin	OHP, Eloxatine, Dacplat, Dacotin, Eloxatin	DNA damaging agent
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Advanced solid tumors (in ovarian expansion)

Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine	B-Vaxx	Immune response against cancer expressing HER2	Clinical Trials

I

Advanced solid tumors (in expansion)

Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

GA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bosutinib	SKI-606, Bosulif	Abl and src family kinase inhibitor	Approved in Other Cancers
Pemetrexed	Pemetrexed disodium, Alimta	DHFR and Thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer

I

Recurrent or persistent serous ovarian cancer

Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
huCART-meso cells		Immune response against cancer expressing mesothelin	Clinical Trials

I

Advanced solid tumors (in expansion)

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies

MI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
APG-1387		SMAC mimetic and IAP antagonist	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Advanced solid tumors (in expansion)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Retifanlimab	MGA012, anti-PD-1 monoclonal antibody MGA012, INCMGA00012	Blocks PD-L1/2 inhibition of T cells	Clinical Trials

I

Recurrent ovarian cancer with disease in the peritoneal cavity or retroperitoneal lymph nodes (in ovarian expansion)

Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Recurrent or persistent FRalpha+ high grade serous ovarian cancer

Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
MOv19-BBz CAR T		Immune response against cancer expressing folate receptor	Clinical Trials

I

Advanced solid tumors (in expansion)

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.

MI, NY, NC, RI, TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
MEDI5752	anti-PD-1/CTLA-4 bispecific antibody MEDI5752	Blocks PD-1 and CTLA-4 inhibition of T cells	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pemetrexed	Pemetrexed disodium, Alimta	DHFR and Thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer

I

Advanced solid tumors (in ovarian expansion)

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

AL, AZ, CT, FL, IN, MI, MN, NJ, NY, TN, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lemzoparlimab	TJC4, TJ011133	Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Recurrent ovarian cancer (amenable to radiation therapy) - without ascites

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Irradiation, Radiotherapy
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

I

Advanced solid tumors with TIPARP AMP (in expansion)

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

CO, CT, FL, MA, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
RBN-2397		PARP7 inhibitor	Clinical Trials

I

Recurrent ovarian cancer with progression on prior PARP inhibitor (inc expansion)

Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer

AL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
M4344	VX-803	ATR kinase inhibitor	Clinical Trials
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

I

Advanced solid tumors (inc ovarian expansion)

A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
NMS-03305293		PARP inhibitor	Clinical Trials

I

Advanced solid tumors (in expansion)

A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination With Ciforadenant, With Pembrolizumab, and With Ciforadenant Plus Pembrolizumab in Adult Subjects With Advanced Cancers

AZ, CA, CT, FL, IL, MD, MA, NV, NY, NC, OH, OK, PA, SC, TN, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ciforadenant	adenosine-A2A receptor antagonist CPI-444, CPI-444	Blocks adenosine A2a receptor inhibition of T cells	Clinical Trials
CPI-006	anti-CD73 monoclonal antibody CPI-006, CPX-006	Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Advanced solid tumors with mutation in TP53 (inc ovarian expansion)

A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors

CA, IN, MN, MO, NY, NC, OK, OR, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AMG 650		KIF18A inhibitor	Clinical Trials

I

Recurrent serous ovarian cancer

A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)

UT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Belinostat	PXD101	HDAC inhibitor	Approved in Other Cancers
Ribociclib	Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali	CDK4/6 inhibitor	Approved in Other Cancers

I

Recurrent ovarian cancer (with peritoneal disease)

Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)

CA, FL, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Doxorubicin	14-Hydroxydaunomycin, Hydroxyl-Daunorubicin	Topoisomerase II inhibitor	Approved in Other Cancers
PIPAC	pressurized intraperitoneal aerosol chemotherapy		Clinical Trials

I

Advanced solid tumors with FGFR2 alterations (in expansion)

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

AZ, CA, FL, IL, MA, MI, MN, NY, OH, PA, TX, UT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
RLY-4008		FGFR2 inhibitor	Clinical Trials

I

Partially platinum sensitive, platinum resistant or refractory ovarian cancer

A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lapatinib	GW2016, GSK572016, lapatinib ditosylate, Tykerb	EGFR and HER2 kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I

Small cell of hypercalcemic type (SCCOHT), clear cell, or endometrioid ovarian cancer with SMARCA4 or ARID1A mutations

Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers

AZ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Seclidemstat	LSD1 inhibitor SP-2577, SP-2577	LSD1 inhibitor	Clinical Trials

I

Advanced solid tumors (in ovarian expansion)

A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer

CT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ICT01		Activates gamma/delta T cells to stimulate immune response	Clinical Trials

I

Advanced MAGE-A4+ solid tumors (in expansion)

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors

MA, MO, NY, NC, OK, PA, TN, TX, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ADP-A2M4CD8	SPEAR T-cell ADP-A2M4CD8, autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells	Immune response against cancer expressing MAGE-A4	Clinical Trials

I

Recurrent BRCA MUT ovarian cancer

Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer

WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dostarlimab	TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

I

Advanced solid tumors (inc ovarian expansion)

Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

AZ, CA, CT, DC, FL, GA, IL, KY, MI, MN, NY, NC, OH, OK, OR, SC, TX, UT, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
JTX-8064		Blocks ILT4 inhibition of immune cells	Clinical Trials
Pimivalimab	anti-PD-1 monoclonal antibody JTX-4014, JTX-4014	Blocks PD-L1/2 inhibition of T cells	Clinical Trials

I

Recurrent high grade serous ovarian cancer

A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

MI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Belinostat	PXD101	HDAC inhibitor	Approved in Other Cancers
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

I

Recurrent ovarian cancer (inc expansion)

Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

FL, OK, TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
DS-6000a		ADC: anti-CDH6 + topoisomerase I inhibitor (Dxd)	Clinical Trials

I

Recurrent ovarian cancer (inc expansion)

Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
GRN-300		SIK2/3 inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I

Advanced solid tumors (inc ovarian expansion)

A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients With Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer

CA, MI, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
TH1902		ADC: anti-SORT1 + microtubule stabilizer/mitotic inhibitor (docetaxel)	Clinical Trials

I

Ovarian cancer with germline BRCA2 or germline PALB2 alterations, or high grade serous or endometrioid ovarian cancer with BRCA1 alterations or other HRD-associated mutations

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pidnarulex	Pol I inhibitor CX5461, RNA Pol I inhibitor CX5461, CX-5461	Pol I inhibitor	Clinical Trials

I

Persistent or recurrent serous ovarian cancer

Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
huCART-meso cells		Immune response against cancer expressing mesothelin	Clinical Trials
VCN-01	PH20 hyaluronidase-expressing adenovirus VCN-01	Induces immune response and tumor cell lysis	Clinical Trials

I

Recurrent ovarian cancer - intraperitoneal infusion

Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin	Proleukin	IL-2 receptor agonist	Approved in Other Cancers
Enoblituzumab	mab MGA271, MGA271	Immune response against cancer expressing B7H3	Clinical Trials
FT516	iPSC-derived non-cleavable CD16 (hnCD16) Fc receptor expressing NK cells FT516	Anti-tumor immune response	Clinical Trials

I

Ovarian cancer with peritoneal disease - expected to undergo complete cytoreduction

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Doxorubicin	14-Hydroxydaunomycin, Hydroxyl-Daunorubicin	Topoisomerase II inhibitor	Approved in Other Cancers
Floxuridine	WR-138720, 5-FUDR	RNA and DNA synthesis inhibitor
HIPEC	Hyperthermic Intraperitoneal Chemotherapy		NCCN Guidelines for Ovarian Cancer
Mitomycin C	Ametycine, MITO-C, Mitocin, Mitolem, Mitosol, Mitozytrex, Mutamycin, NCI-C04706	DNA synthesis inhibitor	Approved in Other Cancers
Oxaliplatin	OHP, Eloxatine, Dacplat, Dacotin, Eloxatin	DNA damaging agent
Surgery			Clinical Trials

I

Recurrent high grade serous ovarian cancer (inc expansion)

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
STRO-002		ADC: anti-FOLR1 + microtubule destabilizer (SC209)	Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.